Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib maintenance in advanced NSCLC
NCT00777179Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Vandetanib with Placebo (2 arms). Primary endpoint: Progression-free Survival Rate at 3 Months. Started Oct 2008; status: completed.
02
Drugs
vandetanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00777179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777179.